UVEITIS FLARE WITH EYES DURING SECOND VACCINATION; This spontaneous case was reported by a consumer and describes the occurrence of UVEITIS (UVEITIS FLARE WITH EYES DURING SECOND VACCINATION) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Panuveitis.    Concurrent medical conditions included Uveitis. Concomitant products included PREDNISONE ACETATE and METHOTREXATE SODIUM (METHOTREXATE [METHOTREXATE SODIUM]) for an unknown indication.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and ADALIMUMAB (HUMIRA) (Subcutaneous) CF. On an unknown date, the patient experienced UVEITIS (UVEITIS FLARE WITH EYES DURING SECOND VACCINATION) (seriousness criterion medically significant). At the time of the report, UVEITIS (UVEITIS FLARE WITH EYES DURING SECOND VACCINATION) had resolved.            This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in  It was unknown if patient was enrolled in a covid-19 vaccine trial. Treatment medications were not reported.   The reporter's causality for the event(s) of uveitis flare with eyes during second vaccination with humira(adalimumab) was no reasonable possibility.  Company Comment:  This is a spontaneous case, reported by a consumer, concerning an adult male patient with relevant medical condition of Non-infectious intermediate, posterior and panuveitis, who experienced the unexpected serious (medically significant) event of Uveitis, reported as uveitis flare up, in the context of the 2 doses of mRNA-1273 vaccine. Latency cannot be properly assessed since vaccination date nor event onset date were provided. No information disclosed on previous COVID-19 vaccination. It was reported that the patient had uveitis flare up after the second COVID-19 vaccination. No further details about the clinical course, diagnostic procedures and treatments were provided. It was reported that the event had resolved. The medical condition of Non-infectious intermediate, posterior, and panuveitis remains as a confounder for uveitis flare up. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This is a spontaneous case, reported by a consumer, concerning an adult male patient with relevant medical condition of Non-infectious intermediate, posterior and panuveitis, who experienced the unexpected serious (medically significant) event of Uveitis, reported as uveitis flare up, in the context of the 2 doses of mRNA-1273 vaccine. Latency cannot be properly assessed since vaccination date nor event onset date were provided. No information disclosed on previous COVID-19 vaccination. It was reported that the patient had uveitis flare up after the second COVID-19 vaccination. No further details about the clinical course, diagnostic procedures and treatments were provided. It was reported that the event had resolved. The medical condition of Non-infectious intermediate, posterior, and panuveitis remains as a confounder for uveitis flare up. The benefit-risk relationship of mRNA-1273 is not affected by this report.